Teva Pharma - Multiplikator Forward P/S TEVA

Teva Pharmaceutical Industries Ltd. (TEVA) - logo korporat

The shift toward innovative biosimilars and cost restructuring is currently defining the market trajectory for Teva Pharmaceutical Industries (TEVA). The company's forward P/S reflects current price momentum, where a metric value of 0.40 confirms the trend's sustainability. This is based on its global status as a generics leader and its proprietary API logistics, which transforms mass-market medications into a reliable cash cow.

TEVA (Teva) riwayat Rasio rega marang pendapatan sing dikarepake saka 04.07.2022 nganti 18.11.2026

Teva Pharmaceutical Industries (TEVA) - rincian metrik lan laporan keuangan

Analisis fundamental perusahaan:Teva Pharmaceuticals (TEVA)
Produk sing diprodhuksi Teva Pharmaceutical Industries Ltd.

The forward P/S reflects market capitalization relative to projected annual revenue, measuring investor confidence in future cash flows. By analyzing the forward P/S of a business, one can assess the extent to which the market is willing to award the company a premium for its operational efficiency and resilience. For Teva Pharmaceutical Industries (TEVA), this multiple accounts for capital expenditures on the environmental modernization of generic production facilities, which impact the final asset value.